Canada's compounding loophole for unapproved peptides

A 2026 CBC News investigation found some Canadian doctors prescribing BPC-157 — a peptide Health Canada has not approved as a drug and has not licensed as a natural health product — through a compounding-policy exemption meant for individualized patient care. The exemption is real and it is Health Canada's own; whether it's being used the way the policy intends is the open question.

The loophole, in plain terms

BPC-157 is not an approved drug in Canada, and it is not licensed as a natural health product (NHP) in any form — injectable, oral or topical. Ordinarily that would be the end of it: no approval, no legal retail sale. A 2026 CBC News investigation found that some doctors are prescribing it anyway, and some pharmacies are compounding it anyway, using a route that doesn't require either kind of approval in the first place.

How a compounding exemption becomes a distribution channel

Health Canada's own Natural Health Product Compounding Policy draws a line between "manufacturing" a product for the market — which needs a product licence (an NPN) — and "compounding," which it treats as a normal part of a practitioner's one-on-one care of a specific patient, and therefore outside that licensing regime. The policy is explicit that this exists so a practitioner can customize a preparation to an individual patient's needs, not as a second door into the market for something that couldn't get through the first one. It says so directly: compounding "must not be used as a means to bypass" federal licensing requirements.

The gap CBC's reporting identifies is that nothing in this framework actually checks whether the ingredient itself has been reviewed for safety or efficacy — only whether the preparation is being made for a specific patient inside a practitioner relationship. A doctor can write a prescription for BPC-157, a compounding pharmacy can prepare it against that prescription, and by Health Canada's own account that sequence sits under the compounding exemption rather than under drug review — even though BPC-157 itself has never been through either approval process the exemption is supposed to sit alongside, not substitute for.

What Health Canada has said and done since

Health Canada's own 9 April 2026 public advisory warns generally against unauthorized injectable peptides — including BPC-157 by name, among a longer list of examples — sold online for anti-aging, weight loss, bodybuilding, recovery and general wellness use, citing risks from hormonal imbalance to organ damage. It doesn't address the compounding-prescription route specifically; that came later, in response to CBC's questions for its 24 July 2026 investigation, when Health Canada said it was looking into whether the advertising CBC found complied with the Food and Drugs Act.

As of this writing, that's where it stands: a stated investigation into specific advertising, and a separate Health Canada consultation on updating its NHP compounding and raw-material policies that closed in July 2026 with no revised policy published yet — not a change to the compounding pathway itself. The exemption CBC's reporting describes remains in place.

Why we're not naming a clinic here

CBC's reporting, using hidden cameras, identified a doctor who discussed BPC-157 with undercover journalists. We're deliberately not repeating that name on this page. This site's policy is that we don't independently name a private clinic or individual as doing something wrong — that's a call for a journalist or a regulator to make, not us, and neither substitutes for the other. Health Canada, as of this writing, has confirmed the general compounding rule and said it's investigating unnamed advertising; it has not itself named a specific clinic or doctor in connection with this story the way it named Canlab Research in a court record. If that changes, we'll cover it the same way we cover any other government enforcement record: naming exactly what the government itself already made public, no more.

If you're offered BPC-157 by a clinic in Canada

A prescription and a compounding pharmacy are real things, but neither one means the underlying substance has been reviewed for safety or efficacy the way an approved drug or a licensed NHP has — for BPC-157 specifically, neither review has happened. See BPC-157's actual evidence base before treating "a doctor can prescribe it" as equivalent to "it's been vetted." The same evidence gap applies regardless of which side of the border you're on — are peptides legal? covers the equivalent US picture, which runs through a similar compounding-eligibility mechanism rather than drug approval.